Tenpoint Therapeutics

Tenpoint Therapeutics

Tenpoint Therapeutics, previously known as Visus Therapeutics Inc., is an ophthalmology-focused biotech firm headquartered in Seattle. Founded without a publicly documented year, the company rebranded to its current name, signaling a broadening of its mission beyond a single product. The CEO Henric Bjarke leads a team with over 150 combined years of ophthalmic experience. The company's lead pipeline candidate is BRIMOCHOL PF, a fixed-dose combination of brimonidine and carbachol formulated as a preservative free eye drop targeting presbyopia — the age-related loss of near vision that impacts over one billion people globally. Tenpoint reported FDA acceptance of a New Drug Application for BRIMOCHOL PF, a milestone that if approved, would place it as a competitor to Vuity (AbbVie) and other emerging presbyopia treatments. The firm's pipeline also includes early-stage programs for cataracts and geographic atrophy, an advanced form of dry age-related macular degeneration. The company partners with eye care professionals and engages contract research organizations for its clinical trials, with a geographic footprint centered in the United States and European clinical sites for its Phase 3 trials. March 2024: Tenpoint Therapeutics announced the appointment of Melissa Epperly as Chief Financial Officer (per firm website, March 2024). The firm has not disclosed AUM, total capital raised, or its current funding stage. Beyond the leadership team, a nine-member board of directors includes David Guyer, Eric Donnenfeld, John de Koning, and others with ties to the ophthalmology and life sciences investor community. No adjacent philanthropic or operating vehicles were disclosed on the firm's public website. Tenpoint Therapeutics differs from most biotech firms in its narrow therapeutic focus — solely on the aging eye — and its choice to develop its own NDA-stage asset rather than acquire late-stage programs from larger partners. The company maintains a lean leadership structure and a board with significant crossover to the ophthalmology field's medical and investment elite.